3-[4-(hydroxymethyl)phenylcarbonyl]pyridine | 218153-10-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[4-(hydroxymethyl)phenylcarbonyl]pyridine
• 英文别名: 4-(Pyridine-3-carbonyl)-benzyl alcohol；[4-(hydroxymethyl)phenyl]-pyridin-3-ylmethanone
• CAS: 218153-10-7
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: WMZGHSAEHSMEGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[4-(hydroxymethyl)phenylcarbonyl]pyridine 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 (4-chloromethyl-phenyl)-pyridin-3-yl-methanone
  参考文献：
  名称：

  Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs

  摘要：

  A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as Ridogrel (1). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00731-4
• 作为产物：
  描述：

  3-氰基吡啶 、 4-bromo-2-(tert-butyldiphenylsilyloxymethyl)benzene 在 正丁基锂 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 3-[4-(hydroxymethyl)phenylcarbonyl]pyridine
  参考文献：
  名称：

  Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs

  摘要：

  A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as Ridogrel (1). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00731-4

文献信息

• [EN] 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS<br/>[FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES SUBSTITUES EN POSITION 6 EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
  申请人：LILLY CO ELI

  公开号：WO2005082859A1

  公开（公告）日：2005-09-09

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: I where: R6 is -C=C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.

  本发明提供了公式I中的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症/强迫性障碍、抑郁症和焦虑症：I其中：R6为-C=C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。
• Triazolo-1,4-diazepine compounds and medicinal composition containing the same
  申请人：Nikken Chemicals Co., Ltd.

  公开号：US06433167B1

  公开（公告）日：2002-08-13

  A triazolo-1,4-diazepine compound having the formula (I): wherein A represents CO, CO—B, or B, B represents a C1 to C6 alkylene group or a C2 to C6 alkylene group having an oxygen atom interposed in the middle thereof, X represents N—O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1 to C6 lower alkyloxy group or a C1 to C6 lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1 represents a hydrogen atom or a C1 to C3 lower alkyl group having both a PAF antagonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.

  一种具有以下式子（I）的三唑并[1,4]二氮杂环化合物：其中A代表CO，CO—B或B，B代表C1到C6烷基或中间有氧原子的C2到C6烷基，X代表N—O或CH，n代表2到6的整数，R代表羟基，C1到C6低烷氧基或C1到C6低烷基氨基，但这些基团可以被取代为N，N-二甲基氨基基团，N，N-二乙基氨基基团，苯基或杂环基团，R1代表氢原子或具有PAF拮抗作用和抑制血栓素合成作用的C1到C3低烷基基团，并且一种含有该化合物作为活性成分的制药组合物。
• 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：Allen John Gordon

  公开号：US20090099155A1

  公开（公告）日：2009-04-16

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is -C≡C-R 10 , -O-R 12 , -S-R 14 , or -NR 24 R 25 ; and other substituents are as defined in the specification.

  本发明提供了式I的6-取代的2,3,4,5-四氢-1H-苯并氮烯作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为-C≡C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。
• 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
  申请人：ALLEN JOHN GORDON

  公开号：US20120028961A1

  公开（公告）日：2012-02-02

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。
• 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
  申请人：Eli Lilly and Company

  公开号：US08022062B2

  公开（公告）日：2011-09-20

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C≡C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.

  本发明提供了式I的6-取代2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6是—C≡C—R10，—O—R12，—S—R14或—NR24R25; 其他取代基如规范中定义。